Core Viewpoint - 康臣药业 has announced a share buyback plan totaling up to HKD 300 million, reflecting confidence in its business development and long-term growth potential [1] Group 1: Share Buyback Plan - The board of 康臣药业 has resolved to execute a share buyback plan on June 13, 2025, with a total fund not exceeding HKD 200 million for repurchasing shares in the open market [1] - An additional share buyback plan was approved on January 29, 2026, allowing for an extra fund of up to HKD 100 million, bringing the total potential fund for share buybacks to HKD 300 million [1] - The duration of the share buyback plan will last from the announcement date until the conclusion of the next annual general meeting or until the shareholders withdraw or amend the buyback authorization [1] Group 2: Business Confidence and Strategic Rationale - The board expresses strong confidence in the company's business development and future prospects, believing that the current share price does not fully reflect its intrinsic value and long-term growth potential [1] - The implementation of the share buyback plan is seen as aligning with the company's long-term development strategy, optimizing capital structure management, and potentially increasing net asset value per share and/or earnings per share, benefiting both the company and its shareholders [1]
康臣药业(01681)拟回购不超3亿港元公司股份